Strategic Growth Square Pharmaceuticals is expanding its manufacturing capacity with new units at the Dhaka site scheduled to be commissioned by end of 2024, signaling increased production capabilities and potential for bulk supply agreements or co-manufacturing partnerships.

Global GMP Presence Solid dosage manufacturing is approved by USFDA, UK MHRA, and MCC South Africa, indicating strong quality and regulatory readiness; this creates opportunities for international contract manufacturing, licensing, and exporting partnerships.

All-in House In-house product development across the portfolio with a robust R&D center and fully developed products for regulated markets; potential sales angle includes premium API or finished-dose collaboration, tech transfer, or co-development with pharma suppliers.

Strategic Alliances Recent and ongoing collaborations with Boehringer Ingelheim and Aristopharma, plus outsourcing arrangements, highlight a receptivity to partnerships and contract manufacturing; target additional co-development or distribution partnerships in regional markets.

Regional Expansion Past investments to establish facilities in Kenya and ongoing Africa market presence suggest a growth-and-diversification strategy; sales opportunities exist in regional distribution, regulatory filing support, and supply-chain services for African and neighboring markets.